Lexicon's IBS drug positive in Phase II trial
13 November 2009
Asher Mullard
Please Login to read the full article.
13 November 2009
Asher Mullard
asher.mullard@informa.com
A Phase II trial of LX1031 in patients with non-constipating irritable bowel syndrome yielded positive Phase II results, says Lexicon Pharmaceuticals. The company's share price was up 19%, to $1.39, in pre-market trading on Nasdaq on November 13th on the news.
"The overall safety and efficacy...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Lexicon replaces irritable bowel lead candidate with follow-on compound
- Alkermes' PhII ALKS-5461: new mechanism, opiate receptor modulation, for refractory depression
- FDA reviewers question proposed study design for Salix's Xifaxan in IBS
- Adolor to begin Phase III of opioid bowel dysfunction drug
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
